AMN
AMN Healthcare Services, Inc.
AMN trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over AMN overall, supported by stronger valuation and stronger modeled upside.
AMN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
AMN's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $29.74 | -21% |
| Current | 14x | $37.42 | — |
| Fair | 16x | $42.98 | +15% |
| Expensive | 32x | $88.16 | +136% |
| Forward | 40x | $37.42 | — |
Historical ranges are pointers, not guarantees.
AMN's PE is in its fair range at 14x. Analysts expect earnings to fall, which would put today's price at 40x next year's earnings, in its expensive range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AMN in the historical PE scenario, which offers more potential upside but is not a forecast.
AMN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Decline | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect AMN's earnings and revenue to decline, with profitability weakening.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over AMN on the outlook, with more favorable valuation and earnings expectations.
AMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.93 | -66% |
| Q3 2026 | $2.76 | +$9.95 |
| Q2 2026 | $2.69 | +$10.46 |
| Q1 2026 | -$0.86 | +$3.47 |
| Q4 2025 | -$2.48 | +$1.37 |
| Q3 2025 | -$7.19 | -596% |
| Q2 2025 | -$7.77 | -392% |
| Q1 2025 | -$4.33 | -214% |
| Q4 2024 | -$3.85 | -172% |
AMN has returned to profit: it earned $2.76 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
AMN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $717.3M | +13% |
| Q2 2026 | $673.2M | +2.3% |
| Q1 2026 | $1.4B | +100% |
| Q4 2025 | $748.2M | +1.8% |
| Q3 2025 | $634.5M | -7.7% |
| Q2 2025 | $658.2M | -11% |
| Q1 2025 | $689.5M | -16% |
| Q4 2024 | $734.7M | -10% |
AMN's revenue is recovering but still below its 2022 peak: $717M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -0.5 points |
| Q2 2026 | 4% | +23 points |
| Q1 2026 | 8.5% | +6.7 points |
| Q4 2025 | 1.1% | +29 points |
| Q3 2025 | 7.5% | +4.3 points |
| Q2 2025 | -19% | -24 points |
| Q1 2025 | 1.8% | -3.1 points |
| Q4 2024 | -28% | -32 points |
AMN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$97.3M | -760% |
| Q2 2026 | -$198.5M | -389% |
| Q1 2026 | $555.2M | +571% |
| Q4 2025 | $67.6M | +19% |
| Q3 2025 | $14.8M | -69% |
| Q2 2025 | $68.7M | -4.8% |
| Q1 2025 | $82.7M | +31% |
| Q4 2024 | $56.6M | +$127.6M |
AMN usually generates cash, though not every quarter: the latest was −$97M, but it generated $327M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AMN on cash flow, with more consistent year-over-year improvement.
AMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +433K shares |
| 1 year | +3.8% | +1.5M shares |
| 3 years | +4.8% | +1.8M shares |
| 5 years | -16% | -7.9M shares |
| Available history | -16% | -7.4M shares |
AMN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $8.4M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $250M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 7.6x | High |
| Q1 2025 | 26.5x | High |
| Q4 2024 | 15.5x | High |
| Q3 2024 | 3.6x | Elevated |
| Q2 2024 | 3.1x | Elevated |
AMN's net debt is about 1.4 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AMN on leverage, with a lower net debt burden relative to earnings.
AMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 50.2 | Neutral |
AMN's weekly RSI is 55 (neutral) and its Stochastic is 50 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMN PE vs Healthcare Sector
| Metric | AMN | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 48% below |
| PE % | 40 | 29 | 11 pts above |
AMN is trading at 14x earnings, a 48% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AMN on valuation relative to its sector.
AMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.6 | 5.6% below |
| 20 week MA | $36.3 | 3% above |
| 50 week MA | $27.5 | 36% above |
| 100 week MA | $24.5 | 53% above |
| 200 week MA | $47.4 | 21% below |
AMN's trend is mixed: it's above three of its five weekly moving averages, and 21% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AMN on trend strength, trading above more of its moving averages.
AMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.7 | $69.3 | +12% |
| 2021 | $69.3 | $122.3 | +77% |
| 2022 | $122.3 | $103.5 | -15% |
| 2023 | $103.5 | $74.9 | -28% |
| 2024 | $74.9 | $24.2 | -68% |
| 2025 | $24.2 | $16.1 | -34% |
| 2026 YTD | $16.1 | $37.4 | +132% |
AMN has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.